{"analyses":[{"groupIds":["OG000","OG001","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.388","statisticalComment":"Adjusted for the stratum to which participants were originally assigned by the Interactive Voice Response System (IVRS)","statisticalMethod":"ANCOVA","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"65.91","value":"-32.91"},{"groupId":"OG001","spread":"29.97","value":"-69.09"},{"groupId":"OG002","spread":"118.32","value":"-41.68"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"25"},{"groupId":"OG002","value":"26"}],"units":"Participants"}],"description":"Percent change from baseline to week 25 urinary N-telopeptide (uNTX) calculated using ((week 25 value - baseline value) / baseline value ) x 100.","dispersionType":"Standard Deviation","groups":[{"description":"Open-label intravenous (IV) bisphosphonate once every 4 weeks (Q4W)","id":"OG000","title":"Bisphosphonate IV Q4W"},{"description":"Open-label denosumab 180 mg by subcutaneous injection once every 12 weeks (Q12W)","id":"OG001","title":"Denosumab 180 mg Q12W"},{"description":"Open-label denosumab 180 mg by subcutaneous injection once every 4 weeks (Q4W)","id":"OG002","title":"Denosumab 180 mg Q4W"}],"paramType":"MEAN","populationDescription":"All participants who are randomized to the treatment phase, receive at least one dose of treatment phase investigational product, and have treatment phase baseline measurements of uNTx and at least one treatment phase post-baseline measurement of uNTx.","reportingStatus":"POSTED","timeFrame":"Baseline, week 25","title":"Percent Change of uNTx (Corrected by Creatinne) From Baseline to Week 25","type":"SECONDARY","unitOfMeasure":"Percent change"}